The World Health Organization recently updated its classification of central nervous system tumors, adding 8 entities, as well as defining new variants and morphologic patterns of existing entities. Despite the continued refinement of brain tumor histologic classification and grading, there remain some diagnostic ''gray zones'' that challenge general surgical pathologists and neuropathologists alike. These include the presence of oligodendroglial features in (mixed) oligoastrocytomas and glioblastomas (GBMs), GBM variants (such as small cell GBM), meningioma classification and grading, medulloblastoma variants, ependymoma grading, the presence of ''neuronal features'' in otherwise morphologically classic gliomas, and low-grade gliomas with high Ki-67 labeling indices. In the current review, we discuss these issues and offer some practical guidelines for dealing with problematic cases.
T he World Health Organization (WHO) recently published the fourth edition of its Classification of Tumors of the Central Nervous System. 1 This new text is notable for its addition of 8 entities to the current classification of brain tumors: (1) angiocentric glioma, (2) atypical choroid plexus papilloma, (3) extraventricular neurocytoma, (4) papillary glioneuronal tumor, (5) rosette-forming glioneuronal tumor of the fourth ventricle, (6) papillary tumor of the pineal region, (7) pituicytoma, and (8) spindle-cell oncocytoma of the adenohypophysis. [2] [3] [4] [5] [6] The fourth WHO classification also recognizes 3 new ''variants'' of previously defined entities (ie, associated with clear differences in biologic behavior), including pilomyxoid astrocytoma, anaplastic medulloblastoma, and medulloblastoma with extensive nodularity. Also newly described are morphologic ''patterns'' (ie, may or may not be associated with altered biology), including glioblastomas (GBMs) with small cell features and GBM with an oligodendroglial component. [2] [3] [4] [5] [6] Grading changes include (1) the elimination of the WHO grade II ganglioglioma (now simplified to include only benign or WHO grade I versus anaplastic or WHO grade III), (2) a shift of pineocytoma to WHO grade I (from II) and a suggestion that pineal parenchymal tumors of intermediate differentiation may be divided into either WHO grade II or III, (3) designation of otherwise benign appearing, brain invasive meningiomas as WHO grade II, (4) a shift of cerebellar neurocytomas to WHO grade II (from I), and (5) clarified criteria for separating hemangiopericytoma, WHO grade II from anaplastic hemangiopericytoma, WHO grade III.
In addition to the rare new entities, variants, morphologic patterns, and grading shifts, there also remain some longstanding controversies that are difficult to resolve, even among the most experienced neuropathologists. These often reflect fundamental philosophical differences in diagnostic approach and a general lack of sufficiently specific biomarkers to resolve the debates in an objective fashion. Not surprisingly, these issues are not easily resolved by consensus WHO guidelines alone, as there may not be a consensus at this time. The major ''gray zones'' in brain tumor classification include, but are not limited to the following: 1. the minimal criteria for presence of an oligodendroglial component in mixed oligoastrocytomas and GBM with an oligodendroglial component, 2. recognizing challenging GBM patterns, such as small cell GBM and GBM with a primitive neuroectodermal tumor (PNET)-like component, 3. meningioma subclassification, 4. minimal criteria for medulloblastoma variants, such as anaplastic and large cell medulloblastomas, 5. ependymoma grading, 6. the presence of neuronal features in otherwise classic gliomas, and 7. histologically low-grade gliomas with high Ki-67 labeling indices.
Although each of these areas is admittedly diagnostically challenging and prone to differences in opinion, there are helpful guidelines and each of these topics is discussed below. Many other gray zones could have been chosen as well, although these were felt to be among the most common problems encountered in surgical neuropathology.
OLIGODENDROGLIAL FEATURES IN MIXED OLIGOASTROCYTOMAS AND GLIOBLASTOMA
The minimal criteria for diagnosing an oligodendroglial component in (mixed) oligoastrocytomas (MOAs) continue to be diagnostically vexing, especially in higher-grade examples. 7 MOAs are graded similarly to pure oligodendrogliomas and require features somewhat vaguely defined by WHO as ''increased cellularity, nuclear atypia, pleomorphism, and mitotic activity.'' 1 Use of these subjective criteria can lead to considerable interobserver variability, particularly in mixed gliomas that contain only scattered mitoses [but r6/10 highpowered field (HPF)]. In a pure astrocytoma, this relatively low mitotic activity would suffice for a WHO grade III designation, often prompting adjuvant radiation and/or chemotherapy for the patient. However, identification of a significant oligodendroglial component in the same tumor (ie, MOA) would only be considered a WHO grade II, where clinical observation is an option, particularly when gross total resection is achieved in a young patient. Presence of microvascular proliferation further complicates the differential diagnosis in this context, as the presence of a significant oligodendroglial component would qualify as anaplastic MOA, WHO grade III. In contrast, a purely astrocytic neoplasm would be designated GBM, WHO grade IV. Thus, the presence of an oligodendroglial component becomes critical not only for morphologic classification, but for grading and therefore, therapy as well. Looking for additional guidance from the literature, Giannini et al 8 have shown that microvascular proliferation and/or Z6 mitoses in 10 HPF within oligodendroglial tumors are associated with statistically significant decreases in patient survival. Therefore, these more objective criteria have been adopted at some institutions, including those of the authors, for determining anaplasia in both pure oligodendrogliomas and MOA.
In terms of minimal criteria for designating an oligodendroglial component, we believe that nuclear cytology is still the most important feature. Low-grade oligodendrogliomas, whether in their pure form or as part of a MOA, have round, uniform nuclei with crisp nuclear membranes, delicate chromatin, and small to inconspicuous nucleoli (Figs. 1B right half, C). The classic clear perinuclear halo is a well-recognized, reproducible artifact of formalin fixation and is a useful diagnostic feature when present. However, it is not required for the diagnosis and, in fact, is typically absent in both frozen section and rapidly fixed specimens.
Anaplastic transformation in oligodendrogliomas is recognized by the criteria outlined above. However, this is often accompanied by cytologic features that are recognizable at low magnification and rarely emphasized in neuropathology textbooks. They become more solid, somewhat nodular, cellular proliferations ( Fig. 1A ) composed of enlarged epithelioid or plasmacytoid cells with moderate amounts of eosinophilic cytoplasm (Figs. 1B left half, D). There may be increased pleomorphism, although careful inspection will reveal that the nuclei still maintain an overall sense of regularity and roundness, although often with more vesicular chromatin and prominent nucleoli.
Immunohistochemical studies may be useful in this differential diagnosis. Glial fibrillary acidic protein (GFAP) is typically either negative in oligodendrogliomas or highlights the cytoplasm of mini-gemistocytes and/or gliofibrillary oligodendrocytes ( Fig. 1E ). Oligodendrogliomas are often, but not invariably nonreactive for p53 protein, such that strong and widespread positivity favors the astrocytomas. Despite a general view that they are purely glial tumors, synaptophysin positivity is also not uncommon ( Fig. 1F ), with rare tumors even displaying morphologically overt neuronal or neurocytic differentiation in the form of rosettes. 9 Molecular genetics have become a useful component for the accurate diagnosis of oligodendroglial neoplasms. 10, 11 Molecular analyses for deletions of chromosomes 1p and 19q, either by fluorescence in situ hybridization or polymerase chain reaction, have now become standard in the diagnostic and prognostic workup of an oligodendroglioma. Loss of chromosome 19q varies from 50% to >80% of cases, whereas loss of 1p ranges from 67% to 92%. [12] [13] [14] [15] However, combined loss of 1p/19q is absent in 10% to 20% of morphologi-cally ''classic'' oligodendrogliomas and is present in only a minority (10% to 20%) of MOA. [16] [17] [18] Thus, the diagnosis of an oligodendroglial component in a mixed glioma still relies more heavily on morphologic than molecular genetic features for diagnosis. 17 GLIOBLASTOMA VARIANTS (SMALL CELL GLIOBLASTOMA, GLIOBLASTOMA WITH OLIGODENDROGLIAL FEATURES, AND GLIOBLASTOMA WITH PRIMITIVE NEUROECTODERMAL TUMORLIKE FEATURES)
The morphologic heterogeneity found in GBM has long been appreciated. Two morphologically distinct variants have historically been recognized as part of the WHO classification: gliosarcoma and giant cell GBM. 1 However, more recently appreciated variants and morphologic patterns include GBM with small cell features, GBM with an oligodendroglial component (Figs. 1G, H), and GBM with features of PNET. 17, [19] [20] [21] [22] [23] Small cell GBM (SC-GBM) refers to a subset of GBM that is not ''multiforme,'' that is; it is striking for its lack of nuclear pleomorphism. SC-GBMs demonstrate surprisingly bland nuclear cytology and morphologic features that FIGURE 2. Small cell glioblastomas are characterized by a uniform population of oval nuclei with deceptively bland chromatin on cytologic preparation (A). Histologically, they may look remarkably oligodendroglioma like at low magnification (B), but on closer inspection feature a ''disconnect'' between the unimpressive nuclear cytology and the high mitotic index (C). Pseudopalisading necrosis provides another clue to its aggressive nature (D), whereas a GFAP immunostain highlights thin cytoplasmic processes not evident on routine H&E sections (E). EGFR gene amplification was seen on FISH studies (F; EGFR gene in red and centromere 7 in green). FISH indicates fluorescence in situ hybridization; GFAP, glial fibrillary acidic protein; H&E, hematoxylin and eosin. overlap greatly with those of oligodendrogliomas, including microcalcifications, ''chicken wire capillaries,'' perinuclear haloes, and perineuronal satellitosis ( Fig. 2 ). 23 Features favoring SC-GBM over oligodendroglioma include the ''disconnect'' between innocuous cytology and brisk mitotic activity, the lack of mucin-filled microcystic spaces, the presence of thin GFAP-positive processes ( Fig. 2E ), epidermal growth factor receptor (EGFR)-vIII immunoreactivity, EGFR gene amplification ( Fig. 2F ), chromosome 10q deletion, and a lack of 1p/19q codeletion. 19, 23 GBM with oligodendroglial features is another controversial topic, but was recently accepted as a morphologic pattern in the WHO 2007 classification scheme, discussed in both the GBM and anaplastic oligoastrocytoma (AOA) chapters. 1 AOA contains 2 neoplastic populations, either intermixed (''diffuse'' variant) or as 2 spatially distinct populations (''compact'' variant). 1 Given the range of cytologic features both cell types can adopt, interobserver variability in the diagnosis of AOA is considerable compared with other gliomas. 18, 24 In an effort to clarify the biologic spectrum of this tumor type, we recently studied 1093 high-grade gliomas and found that AOA with necrosis did considerably worse than AOAs without necrosis, but better than conventional GBMs. Mean survival for patients with traditional GBMs was 10 months, compared with roughly 2 and >7 years for ''AOAs with and without necrosis,'' respectively. 17 Although such tumors have sometimes been designated grade IV oligoastrocytomas, the currently preferred nomenclature of the WHO is ''GBM with an oligodendroglioma component.''
Finally, it has recently been recognized that a subset of malignant gliomas (most often GBMs) contains neuroblastic or PNET-like foci (Fig. 3) . These foci consist of discrete hypercellular nodules, often with Homer Wright rosettes, synaptophysin immunopositivity, and MYC gene amplifications. 20 Many of these tumors also show features reminiscent of anaplastic medulloblastoma (an entity discussed further below), including cell wrapping, increased cell size, nucleolar prominence, and pleomorphism. A recent case report suggested an association of such tumors with JC virus, 25 although this hypothesis requires additional study. We have recently described a series of 53 such tumors and found that they are associated with a significantly increased risk of cerebrospinal fluid dissemination and potentially, a response to platinum-based chemotherapeutics. 20 
MENINGIOMA CLASSIFICATION AND GRADING
The most recent version of the WHO brain tumor classification system has made only a few changes in the classification and grading of meningiomas in comparison to the major changes made in the 2000 scheme. Perhaps the most significant clarification is that brain invasive meningiomas are now considered WHO grade II tumors, even if otherwise histologically benign. Brain invasion is defined as ''irregular, tonguelike protrusions of tumor cells, infiltrating underlying parenchyma, without an intervening layer of leptomeninges'' 1 (Fig. 4A ). Brain invasion as a sign of malignancy in meningiomas has long been debated, with opinions ranging from it being a defining feature of malignancy to ignoring it altogether for grading purposes. Two large series from the Mayo Clinic demonstrated that brain invasion is a statistically significant predictor of increased recurrence and shorter overall survival, even in the absence of frank anaplasia. Such tumors are prognostically similar to grade II (atypical) meningiomas, given that the estimated recurrence-free and overall survival times were essentially identical to more classically defined atypical meningiomas. 26, 27 Accurate diagnosis of brain invasion is therefore critical and in borderline cases, an immunohistochemical stain for GFAP can be very helpful in delineating entrapped glial elements within the substance of a brain-invasive meningioma (Fig. 4B) .
No newly recognized variants of meningiomas were included in the 2007 WHO classification system. Rare morphologic patterns, such as oncocytic meningiomas, have been suggested as being more aggressive (Fig. 4C ), but this was not confirmed in a second series and it was not felt that there was sufficient clinical experience to sanction this variant at this time. 28, 29 On the other hand, the rare lymphoplasmacyte-rich variant (Fig. 4D) , although listed as a WHO grade I meningioma, remains a controversial entity as its behavior is sometimes more like that of an inflammatory process than a tumor (ie, meningothelial hyperplasia in response to an inflammatory condition). 30, 31 One of the remaining gray zones in meningioma grading pertains to the 4 recognized aggressive variants. For these WHO grade II (chordoid and clear cell) and III (papillary and rhabdoid) meningiomas, how much of the tumor must be present before the tumor is automatically upgraded? For example, it is not uncommon to find partially developed or even fully developed features of these meningioma subtypes focally, within otherwise benign appearing tumors. The previously reported series have essentially focused on tumors with widespread and fully developed chordoid, clear cell, papillary, or rhabdoid changes. At present, there are no studies that adequately address this phenomenon, but it was the general feeling of WHO participants that such focal findings do not necessarily have the same significance. We therefore recommend using the recommended WHO grades only when the majority of the tumor (ie, >50%) shows the appropriate histologic features.
MEDULLOBLASTOMA VARIANTS
Medulloblastoma is the prototype ''small round blue cell tumor'' of the central nervous system. The 2007 WHO classification recognizes 4 variants: desmoplastic/ nodular medulloblastoma, medulloblastoma with extensive nodularity, anaplastic medulloblastoma, and large cell medulloblastoma. Medullomyoblastoma and melanocytic medulloblastoma are no longer considered variants, but instead are recognized as morphologic patterns, as there is not a clear association with modified biologic behavior. 1, 6 It is suggested that the descriptive term ''medulloblastoma with myogenic differentiation'' be used for any variant of medulloblastoma that contains rhabdomyoblastic elements (recognized morphologically and confirmed by immunohistochemistry). 6 The presence of melanin-producing cells (eg, pigmented retinal epithelium) may be seen in several of the medulloblastoma variants and is also considered merely an unusual form of differentiation. 6 The descriptive term ''medulloblastoma with melanotic differentiation'' has been similarly recommended for this pattern.
The 2 newly recognized variants of medulloblastoma, medulloblastoma with extensive nodularity, and anaplastic medulloblastoma, are worth noting because of significant prognostic implications. Medulloblastoma with extensive nodularity was previously reported as ''cerebellar neuroblastoma'' by some and can be considered an exaggerated form of the desmoplastic/nodular medulloblastoma with extensive neuronal maturation, similar to that of the differentiating neuroblastoma in the peripheral nervous system. It differs from the latter by its considerably larger, often grossly and radiologically visible (resembling a ''bunch of grapes'') reticulin-free, neuropil-rich nodules with extensive neurocytic and sometimes ganglion cell differentiation (Fig. 5A) . In contrast, the internodular reticulin-rich regions are considerably smaller with only a limited fraction of primitive ''small blue cells.'' 6 This variant is extremely rare and encountered most often in infants. When fully developed, the extensively nodular variant is associated with a more favorable prognosis. 32, 33 Whether or not the more common desmoplastic/nodular variant (Figs. 5B-F) is similarly more favorable has long been controversial, although a recent large series suggests that such tumors have a bimodal peak (infancy and adulthood) and are indeed associated with slightly better patient survival. 33 Such tumors harbor classic ''pale islands'' that resemble germinal centers in a lymph node at low magnification. These microscopically evident islands are similarly reticulin-free zones of limited neuronal maturation (more synaptophysin positive and lower Ki-67 indices), but are surrounded by a reticulin-rich (ie, desmoplastic) internodular zone composed of more primitive elements (less synaptophysin, higher Ki-67 activity). 1 The anaplastic variant is characterized by increased cell size, significant nuclear pleomorphism (similar to the definition of anaplastic Wilms tumor), and cell wrapping (Fig. 5G ), often associated with very high mitotic and apoptotic activity. 1, 32 Of note, the presence of anaplasia is not incompatible with the presence of classic Homer Wright rosettes. 32 The large cell variant is also characterized by increased cell size, but is associated with oval, vesicular nuclei containing prominent nucleoli (Fig. 5H) . Anaplastic and large cell features often coexist within the same tumor. 34 Because these variants have partially overlapping morphologic features, similar negative prognostic features, and share genetic features, some authors have advocated the term ''large cell/anaplastic medulloblastoma.'' 35, 36 However, the WHO has kept them as separate entities for the time being. In both cases, patients are more likely to develop cerebrospinal fluid dissemination (often at presentation), less likely to respond to standard medulloblastoma therapy, and have shorter overall survival times. [34] [35] [36] [37] The tumors often harbor isochromosome 17q and MYC gene amplifications (either c-myc or N-myc), genetic alterations that have similarly been associated with poor prognosis. 32, 33, 38, 39 
EPENDYMOMA GRADING
Ependymomas are relatively discrete tumors that are generally, but not invariably associated with the ventricular system. They have a predilection for children and young adults and are characterized histologically by the presence of perivascular pseudorosettes, wherein tumor cells form thin eosinophilic processes arranged radially around blood vessels, creating perivascular nuclear-free zones. 1 The current WHO classification system divides ependymomas into grades II and III (the latter designated anaplastic ependymomas), but the criteria for anaplasia is a subject of debate. It appears that a high mitotic rate (at least 5 mitoses/10 HPF), microvascular proliferation, and the presence of areas of hypercellular, less differentiated tumor correlate best with poor outcome. [40] [41] [42] Of interest, necrosis is fairly common and is not associated with the same ominous implications as seen in astrocytomas, perhaps with the exception of pseudopalisading necrosis.
In larger series, ependymoma grade has been associated with prognosis, hence the need for accurate grading criteria. Tihan et al 43 most recently demonstrated that histologic grade was 1 of 3 parameters (the other 2 being extent of resection and age) that were independent prognostic values for event-free survival. Other studies have found similar results, some associated with overall survival as well. [44] [45] [46] [47] [48] [49] [50] [51] [52] Given the importance of accurate grading, we advocate assessing ependymomas carefully for mitotic figures, including the use of Ki-67 immunohistochemical stains in borderline examples and careful examination of the tumor for focal anaplasia.
THE PRESENCE OF NEURONAL FEATURES IN OTHERWISE CLASSIC GLIOMAS
In the last few years, the category of glioneuronal tumors has been rapidly expanding, with some entities having clearly distinctive morphologic features. However, the increased use of immunohistochemical studies has challenged some of our traditional views of even the more classic gliomas. It is well known that neuronal markers vary significantly in terms of sensitivities and specificities. As many also highlight entrapped neuropil and nonneoplastic neurons, this may also lead to overinterpretation of a neuronal component in a diffuse glioma. Beyond these technical difficulties, however, there remains an increased recognition that true expression of neuronal markers may be seen in otherwise classic diffuse gliomas, especially synaptophysin positivity in oligodendrogliomas. 9, 10, 53 In fact, it has been recently recognized that a paranuclear dotlike pattern of immunoreactivity is often associated with oligodendrogliomas showing 1p and 19q deletions (Fig. 1F ). 54 A growing number of studies support the contention that diffuse gliomas can in fact undergo neuronal differentiation and probably do so much more often than previously appreciated. With this in mind, should such tumors now be reclassified as ''glioneuronal tumors?'' We would argue no, because the classic entities are already well established, well recognized by clinicians with an anticipated clinical behavior, and associated with clear therapeutic implications. To date, there have been no demonstrable effects on biologic behavior for the diffuse gliomas with versus without these neuronal features, especially those where the latter simply represent unexpected immunohistochemical results.
A smaller cohort of gliomas likely represents an exaggerated form of the tumors discussed above in that clear morphologic features of neuronal differentiation are also evident. For example, the glioneuronal tumor with neuropil-like islands represents a group of both low-grade (diffuse astrocytomas) and high-grade tumors (anaplastic astrocytomas, GBMs) with rounded neurocytic cells surrounding and/or embedded within sharply delimited islands of neuropil that stain positively for synaptophysin and other neuronal markers (neurofilament protein, Neu-N). [55] [56] [57] [58] The glial component of these tumors can have both fibrillary and gemistocytic elements and these tumors generally behave based on the underlying glioma component. The neuronal component does not, for now, seem to carry significant prognostic weight. The same seems to be true for oligodendrogliomas (often anaplastic) with neurocytic differentiation. 9,10 Many of these tumors harbor chromosome 1p/19q codeletion and behave like oligodendrogliomas in general.
HISTOLOGICALLY LOW-GRADE TUMORS WITH HIGH KI-67 LABELING INDICES
Historically, the MIB-1/Ki-67 labeling index (LI) increases proportionally with tumor grade. For instance, diffuse astrocytomas (WHO grade II) generally have a LI less than 5%, with a reported mean of 2.5%. 1 Anaplastic astrocytomas (WHO grade III) typically have a LI in the range of 5% to 10%, although the values vary considerably, even within different regions of the tumor itself. [59] [60] [61] [62] GBMs (WHO grade IV) also can show extensive heterogeneity, although the mean LI is generally between 10% and 20%. 60, 61, [63] [64] [65] [66] Numerous studies have shown that LI is highly correlated with tumor grade and is therefore a useful ancillary stain, used in conjunction with histologic features to determine the grade of a tumor. 65, [67] [68] [69] [70] [71] [72] Unfortunately, there remains great technical variability in staining and assessment of Ki-67, making it difficult to translate LI cutoffs from one laboratory to another. It is for this reason that the WHO does not use Ki-67 as part of the grading criteria for brain tumors. Nevertheless, there is general agreement that it can be very useful, particularly if one gets experience using their own material, such that they become familiar with what constitutes a clearly elevated LI. It is therefore with this major disclaimer in mind that we would offer the overly simplistic generalization that labeling indices <5% are low, 5% to 10% are moderate, and >10% are high.
Another difficulty arises when the tumor histology is discordant with the observed LI. The situation is easier when faced with a malignant appearing tumor for which mitoses are difficult to find, as a high Ki-67 stain often provides welcome support for the suspected high-grade diagnosis. Similarly, a high-grade glioma with extensive cellular pleomorphism, pseudopalisading necrosis, and vascular proliferation should not be ''down-graded,'' simply because mitoses are infrequent and the Ki-67 LI is low. The more difficult situation occurs when the pathologist is faced with what seems to be a low-grade glioma (or other low-grade tumor type), but shows a surprisingly high Ki-67 LI. Given issues of heterogeneity, one must make sure that all tissue has been submitted. A review of the radiology may also be helpful, as WHO grade II gliomas will generally not enhance, whereas many of the higher-grade examples will. When dealing with a tumor that is histologically consistent with WHO grade II, but has an elevated LI and/or imaging features suggesting a higher grade (eg, contrast enhancement), we typically sign out such cases as WHO grade II based on strict criteria, but add to the diagnostic line: ''ywith elevated Ki-67 LI (see comment).'' In the comment, we state that the increased proliferative index is worrisome and may represent either early anaplastic transformation or an artifact of undersampling in a higher-grade neoplasm. As such, the tumor may behave more aggressively than the standard WHO grade II glioma and close clinical follow-up is recommended.
